2 Magnificent Quantum Computing Stocks to Buy and Hold for 10 Years

IonQ and IBM are presented as long-term quantum-computing investments, supported by IonQ's new Superion 256 trapped-ion platform and its successful photonic linking of two independent quantum systems. IBM has committed more than $10 billion to quantum computing over the next five years and targets delivery of its fault-tolerant Quantum Starling system in 2029, designed for roughly 20,000 times more operations than current machines. The investment case is driven by potential quantum adoption in optimization, drug discovery, chip design, finance and logistics, though commercialization remains a long-dated and uncertain opportunity.

Analysis

The investable distinction is not quantum exposure but financing and execution risk. IONQ’s equity value is effectively a long-duration option on technical milestones, so changes in booking quality, delivery timing, and cash burn can drive the stock far more than incremental research announcements. SKYT gains a potentially valuable customer-validation channel, but quantum volumes are unlikely to move its utilization or margin profile materially within the next 12-24 months; the relevant catalyst is a multiyear manufacturing agreement with committed capacity and economics.

IBM can fund quantum development from existing cash generation, making the technology primarily a multiple-support and enterprise-retention lever rather than a near-term earnings driver. The more important second-order beneficiary is IBM’s hybrid computing stack: quantum pilots can deepen relationships that also pull through consulting, mainframe, cloud and AI infrastructure. That makes IBM better positioned than pure plays if commercially useful quantum workloads remain delayed, while IONQ faces dilution risk if its revenue ramp fails to outrun R&D and capex needs.

Consensus likely overweights qubit-count and roadmap headlines and underweights error correction, customer ROI, and integration into classical workflows. Over the next 1-3 months, industry enthusiasm can sustain IONQ momentum, but a 6-18 month rerating requires independently disclosed backlog conversion, gross-margin progression, and narrowing cash use. For IBM, the falsification point is not a missed distant technical target; it is evidence that quantum spending is displacing higher-return software/AI investment or fails to produce measurable enterprise contract expansion.

Key Decisions for Investors

• Prefer a 6-12 month long IBM / short IONQ pair for risk-adjusted quantum exposure: IBM provides downside ballast from diversified earnings while the short leg hedges speculative quantum-beta compression. Reassess if IONQ reports sustained commercial revenue acceleration with improving gross margin and at least 18 months of liquidity without expected equity issuance.
• Do not initiate a directional IONQ long solely on technical announcements. Place an alert around the next earnings release for signed backlog, delivery schedule, cash burn, and customer concentration; only upgrade on verifiable contract conversion rather than management-defined performance metrics.
• Maintain a small watch position in SKYT rather than treating it as a quantum proxy. Upgrade only if a disclosed IonQ-related production commitment is large enough to affect wafer utilization or revenue guidance; absent that, the relationship is strategically interesting but financially immaterial.
• For IBM, add on post-earnings weakness only if constant-currency software growth, free-cash-flow guidance, and AI/consulting bookings remain intact. The risk/reward is unattractive if quantum investment coincides with weaker core margins or a lower capital-return framework.